Skip to main content
SpringerLink
Log in

ICER posts on muscular dystrophy, Zolgensma

  • News item
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. see PharmacoEconomics & Outcomes News 826 p2; 803386366

References

  1. Institute for Clinical and Economic Review. ICER Releases Draft Evidence Report on Treatments for Duchenne Muscular Dystrophy. Internet Document : 27 May 2019. Available from: URL: https://icer-review.org/announcements/dmd_draft_evidence_report/

  2. Institute for Clinical and Economic Review. ICER Comments on the FDA Approval of Zolgensma for the Treatment of Spinal Muscular Atrophy. Internet Document : 27 May 2019. Available from: URL: https://icer-review.org/announcements/icer_comment_on_zolgensma_approval/

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

ICER posts on muscular dystrophy, Zolgensma. PharmacoEcon Outcomes News 829, 2 (2019). https://doi.org/10.1007/s40274-019-5916-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-019-5916-4

Search

Navigation